The first and potent CXCR4 antagonist, Plerixafor, is Food and Drug Administration (FDA) approved for Stem Cell Mobilization in patients with Multiple Myeloma and Non-Hodgkin lymphoma. The gene discussed is CXCR4; the disease is non-Hodgkin lymphoma.